Wellcome Genome Campus
About CongenicaCongenica is a UK company founded on pioneering research from the Wellcome Trust Sanger Institute, NHS clinicians and regional genetic testing laboratories. We’ve translated this research into the gold standard clinical genomic analytics platform, Sapientia®, providing integration of human DNA sequences with deep clinical phenotyping, enabling clinicians to provide actionable interpretation of genetic disease for patients.
CEO: Thomas Weaver
COO: Nick Lench
Please click here for Congenica's products.
18 articles with Congenica
Congenica Co-founder and Scientific Director Dr Matthew Hurles Elected to Fellowship of the Royal Society
Congenica, the global diagnostic decision support platform provider, congratulates its co-founder and Scientific Director, Dr Matthew Hurles, FMedSci FRS, who has been elected to Fellowship of the Royal Society, the UK’s most prestigious scientific organisation.
Congenica, the global diagnostic decision support platform provider, has announced that it now offers an on-premise deployment method in addition to cloud deployment for running its SapientiaTM platform.
Epilepsy Society, UCL and Congenica Join Forces in Genomic Study to Identify Causes of Unexpected Deaths in Epilepsy
Sudden unexpected death in epilepsy (SUDEP) occurs in approximately 1/1000 people with epilepsy and is poorly understood
Genomics England names Congenica as its Clinical Decision Support Service partner for the delivery of the NHS Genomic Medicine Service
Congenica Announces Market Access Partnership with Digital China Health to Enable Genomic Medicine in the Chinese Market
Partnership will accelerate Congenica’s commercial expansion in the Chinese market
Congenica, the global provider of clinical genomics interpretation software, today announced the appointment of Mrs Wendy Britten as its new Chief Financial Officer (CFO), effective 1st September, 2018.
Congenica and SFI Research Centre FutureNeuro Unite to Deliver More Accurate Diagnoses for Genetic Epilepsy
The alliance between Congenica and FutureNeuro, will further help the evolving understanding of the causes of many types of epilepsy and will also help to progress the exciting clinical alliance between genomics and electronic health records.
The meeting was held in conjunction with the State visit of Prime Minister May.
Congenica today announced the appointment of its new Chief Executive Officer, David Atkins, Ph.D. Based at the Company’s headquarters in Cambridge, UK.
Congenica’s Sapientia Selected By Coimbra Paediatric Hospital For Portugal’s In2genome Genetic Disease Diagnosis Project
Congenica Completes Series B Financing Round With Investments From China-Based BGI Healthlink And Future Planet
Congenica Raises £8M ($10M) In Series B Financing Round To Drive International Expansion Of Its Genome Analysis Business
Congenica Release: Sapientia Detecting Clinically Relevant Variants In 35% Of First Diagnostic Reports Delivered To UK 100,000 Genomes Project